Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPhA’s Deficit Reduction Proposals Focus On Medicare Low-Income Subsidy, REMS Policies

This article was originally published in The Pink Sheet Daily

Executive Summary

In letters to congressional leaders, generic drug trade group outlines six proposals that it says would save the government billions of dollars and lessen the impact of sequestration cuts.

You may also be interested in...



Brand, Generic Disputes Over Access Move Beyond REMS Restrictions

Generic companies say innovators are using voluntary restricted distribution programs to prevent them from obtaining reference drugs for bioequivalence testing; a July hearing is set in a dispute involving Actelion’s Gaucher disease drug Zavesca, which is not subject to a Risk Evaluation and Mitigation Strategy.

Raising Part D Donut Hole Discounts To 75% Proposed By President

President Obama’s 2014 budget plan contains some new drug reimbursement ideas, including increasing the brand drug discount used in the Medicare Part D donut hole to 75% and slashing the Part B drug rate to ASP+3%.

Raising Part D Donut Hole Discounts To 75% Proposed By President

President Obama’s 2014 budget plan contains some new drug reimbursement ideas, including increasing the brand drug discount used in the Medicare Part D donut hole to 75% and slashing the Part B drug rate to ASP+3%. Many familiar proposals are reprised – a stronger IPAB, mandatory drug rebates for Medicare/Medicaid dual-eligibles, eliminating pay-for-delay generic drug deals and reducing biologic product exclusivity.

Related Content

Topics

UsernamePublicRestriction

Register

PS075425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel